Current Report Filing (8-k)
23 December 2021 - 3:21AM
Edgar (US Regulatory)
NONE0001564824false00015648242021-12-212021-12-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
Date of Report (Date of earliest event reported): December 21, 2021
|
Allakos Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
Delaware
|
001-38582
|
45-4798831
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
975 Island Drive, Suite 201
|
|
|
Redwood City, California
|
|
94065
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
Registrant’s Telephone Number, Including Area Code: 650 597-5002
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001
|
|
ALLK
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
Release of Study Results
On December 21, 2021, Allakos Inc. (the “Company”) issued a press release announcing its topline Phase 3 data from the ENIGMA 2 study of lirentelimab in patients with eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 data from the KRYPTOS study of lirentelimab in patients with eosinophilic esophagitis met histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
Allakos Inc.
|
|
|
|
|
|
|
Date:
|
December 21, 2021
|
By:
|
/s/ H. Baird Radford, III
|
|
|
|
|
H. Baird Radford, III
Chief Financial Officer
|
Allakos (NASDAQ:ALLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allakos (NASDAQ:ALLK)
Historical Stock Chart
From Apr 2023 to Apr 2024
